Now showing items 177-196 of 687

    • Detection of cyclin D1 in B cell lymphoproliferative disorders by flow cytometry 

      Jain, P; Giustolisi, GM; Atkinson, S; Elnenaei, MO; Morilla, R; Owusu-Ankomah, K; Rafiq-Mohammed, F; Matutes, E; Wotherspoon, A; Catovsky, D (BRITISH MED JOURNAL PUBL GROUP, 2002-12)
      Aims: To describe and revise a flow cytometric assay for evaluating cyclin D1 overexpression in B cell lymphoproliferative disorders (B-LPDs), Methods: Cyclin D1 expression was evaluated in 11 healthy controls and 5 1 ...
    • Detection of the prodrug-activating enzyme carboxypeptidase G2 activity with chemical exchange saturation transfer magnetic resonance. 

      Jamin, Y; Eykyn, TR; Poon, E; Springer, CJ; Robinson, SP (2014-04)
      PURPOSE:The purpose of this study is to evaluate if the differential exchange rates with bulk water between amine and amide protons can be exploited using chemical exchange saturation transfer magnetic resonance (CEST-MR) ...
    • Determinants of age at menarche in the United Kingdom: analyses from the Breakthrough Generations Study 

      Ashworth, A; Jones, M; Schoemaker, M; Swerdlow, A (2010)
      Background: Early menarche increases breast cancer risk but, aside from weight, information on its determinants is limited. Methods: Age at menarche data were collected retrospectively by questionnaire from 81 606 women ...
    • Deterministic Evolutionary Trajectories Influence Primary Tumor Growth: TRACERx Renal. 

      Turajlic, S; Xu, H; Litchfield, K; Rowan, A; Horswell, S; Chambers, T; O'Brien, T; Lopez, JI; Watkins, TBK; Nicol, D; Stares, M; Challacombe, B; Hazell, S; Chandra, A; Mitchell, TJ; Au, L; Eichler-Jonsson, C; Jabbar, F; Soultati, A; Chowdhury, S; Rudman, S; Lynch, J; Fernando, A; Stamp, G; Nye, E; Stewart, A; Xing, W; Smith, JC; Escudero, M; Huffman, A; Matthews, N; Elgar, G; Phillimore, B; Costa, M; Begum, S; Ward, S; Salm, M; Boeing, S; Fisher, R; Spain, L; Navas, C; Grönroos, E; Hobor, S; Sharma, S; Aurangzeb, I; Lall, S; Polson, A; Varia, M; Horsfield, C; Fotiadis, N; Pickering, L; Schwarz, RF; Silva, B; Herrero, J; Luscombe, NM; Jamal-Hanjani, M; Rosenthal, R; Birkbak, NJ; Wilson, GA; Pipek, O; Ribli, D; Krzystanek, M; Csabai, I; Szallasi, Z; Gore, M; McGranahan, N; Van Loo, P; Campbell, P; Larkin, J; Swanton, C; TRACERx Renal Consortium (2018-04-12)
      The evolutionary features of clear-cell renal cell carcinoma (ccRCC) have not been systematically studied to date. We analyzed 1,206 primary tumor regions from 101 patients recruited into the multi-center prospective study, ...
    • Development of a targeted sequencing approach to identify prognostic, predictive and diagnostic markers in paediatric solid tumours. 

      Izquierdo, E; Yuan, L; George, S; Hubank, M; Jones, C; Proszek, P; Shipley, J; Gatz, SA; Stinson, C; Moore, AS; Clifford, SC; Hicks, D; Lindsey, JC; Hill, RM; Jacques, TS; Chalker, J; Thway, K; O'Connor, S; Marshall, L; Moreno, L; Pearson, A; Chesler, L; Walker, BA; De Castro, DG (2017-12-06)
      The implementation of personalised medicine in childhood cancers has been limited by a lack of clinically validated multi-target sequencing approaches specific for paediatric solid tumours. In order to support innovative ...
    • Development of combination therapies to maximize the impact of KRAS-G12C inhibitors in lung cancer. 

      Molina-Arcas, M; Moore, C; Rana, S; van Maldegem, F; Mugarza, E; Romero-Clavijo, P; Herbert, E; Horswell, S; Li, L-S; Janes, MR; Hancock, DC; Downward, J (2019-09)
      KRAS represents an excellent therapeutic target in lung cancer, the most commonly mutated form of which can now be blocked using KRAS-G12C mutant-specific inhibitory trial drugs. Lung adenocarcinoma cells harboring KRAS ...
    • Development of the SIOPE DIPG network, registry and imaging repository: a collaborative effort to optimize research into a rare and lethal disease. 

      Veldhuijzen van Zanten, SEM; Baugh, J; Chaney, B; De Jongh, D; Sanchez Aliaga, E; Barkhof, F; Noltes, J; De Wolf, R; Van Dijk, J; Cannarozzo, A; Damen-Korbijn, CM; Lieverst, JA; Colditz, N; Hoffmann, M; Warmuth-Metz, M; Bison, B; Jones, DTW; Sturm, D; Gielen, GH; Jones, C; Hulleman, E; Calmon, R; Castel, D; Varlet, P; Giraud, G; Slavc, I; Van Gool, S; Jacobs, S; Jadrijevic-Cvrlje, F; Sumerauer, D; Nysom, K; Pentikainen, V; Kivivuori, S-M; Leblond, P; Entz-Werle, N; von Bueren, AO; Kattamis, A; Hargrave, DR; Hauser, P; Garami, M; Thorarinsdottir, HK; Pears, J; Gandola, L; Rutkauskiene, G; Janssens, GO; Torsvik, IK; Perek-Polnik, M; Gil-da-Costa, MJ; Zheludkova, O; Shats, L; Deak, L; Kitanovski, L; Cruz, O; Morales La Madrid, A; Holm, S; Gerber, N; Kebudi, R; Grundy, R; Lopez-Aguilar, E; Zapata-Tarres, M; Emmerik, J; Hayden, T; Bailey, S; Biassoni, V; Massimino, M; Grill, J; Vandertop, WP; Kaspers, GJL; Fouladi, M; Kramm, CM; van Vuurden, DG; members of the SIOPE DIPG Network (2017-04)
      Diffuse intrinsic pontine glioma (DIPG) is a rare and deadly childhood malignancy. After 40 years of mostly single-center, often non-randomized trials with variable patient inclusions, there has been no improvement in ...
    • Development Refractoriness of MLL-Rearranged Human B Cell Acute Leukemias to Reprogramming into Pluripotency. 

      Muñoz-López, A; Romero-Moya, D; Prieto, C; Ramos-Mejía, V; Agraz-Doblas, A; Varela, I; Buschbeck, M; Palau, A; Carvajal-Vergara, X; Giorgetti, A; Ford, A; Lako, M; Granada, I; Ruiz-Xivillé, N; Rodríguez-Perales, S; Torres-Ruíz, R; Stam, RW; Fuster, JL; Fraga, MF; Nakanishi, M; Cazzaniga, G; Bardini, M; Cobo, I; Bayon, GF; Fernandez, AF; Bueno, C; Menendez, P (2016-10)
      Induced pluripotent stem cells (iPSCs) are a powerful tool for disease modeling. They are routinely generated from healthy donors and patients from multiple cell types at different developmental stages. However, reprogramming ...
    • Diagnostic issues in chronic lymphocytic leukaemia (CLL) 

      Matutes, E; Catovsky, D (ELSEVIER SCI LTD, 2010-03)
      The diagnosis of chronic lymphocytic leukaemia (CLL) is based on clinical and laboratory features. Morphology and immunophenotype are the initial diagnostic investigations. In atypical cases, these tests should be complemented ...
    • Diagnostic significance of CD20 and FMC7 expression in B-cell disorders 

      Delgado, J; Matutes, E; Morilla, AM; Morilla, RM; Owusu-Ankomah, KA; Rafiq-Mohammed, F; del Giudice, I; Catovsky, D (AMER SOC CLINICAL PATHOLOGY, 2003-11)
      We analyzed by flow cytometry the expression of CD20 and FMC7 in cell suspensions from 932 patients, including 630 cases of chronic lymphocytic leukemia (CLL), 23 cases of other B-cell leukemias, and 279 cases of B-cell ...
    • Dickkopf-3 links HSF1 and YAP/TAZ signalling to control aggressive behaviours in cancer-associated fibroblasts. 

      Ferrari, N; Ranftl, R; Chicherova, I; Slaven, ND; Moeendarbary, E; Farrugia, AJ; Lam, M; Semiannikova, M; Westergaard, MCW; Tchou, J; Magnani, L; Calvo, F (2019-01-10)
      Aggressive behaviours of solid tumours are highly influenced by the tumour microenvironment. Multiple signalling pathways can affect the normal function of stromal fibroblasts in tumours, but how these events are coordinated ...
    • Differential diagnosis in chronic lymphocytic leukaemia 

      Matutes, E (ELSEVIER SCIENCE BV, 2007-09)
      The diagnosis of chronic lymphocytic leukaemia (CLL) is based on clinical and laboratory features. Morphology and immunophenotype are the key initial diagnostic tests. In cases with atypical features, these investigations ...
    • Diffuse gliomas classified by 1p/19q co-deletion, TERT promoter and IDH mutation status are associated with specific genetic risk loci. 

      Labreche, K; Kinnersley, B; Berzero, G; Di Stefano, AL; Rahimian, A; Detrait, I; Marie, Y; Grenier-Boley, B; Hoang-Xuan, K; Delattre, J-Y; Idbaih, A; Houlston, RS; Sanson, M (2018-05)
      Recent genome-wide association studies of glioma have led to the discovery of single nucleotide polymorphisms (SNPs) at 25 loci influencing risk. Gliomas are heterogeneous, hence to investigate the relationship between ...
    • Direct interaction of FANCD2 with BRCA2 in DNA damage response pathways 

      Ashworth, A (2004-06)
      Direct interaction of FANCD2 with BRCA2 in DNA damage response pathways Fanconi anaemia (FA) is a chromosomal instability disorder characterized by cellular sensitivity to DNA interstrand crosslinking agents and a high ...
    • Directing the use of DDR kinase inhibitors in cancer treatment. 

      Brandsma, I; Fleuren, EDG; Williamson, CT; Lord, CJ (2017-12)
      <label>INTRODUCTION</label>Defects in the DNA damage response (DDR) drive the development of cancer by fostering DNA mutation but also provide cancer-specific vulnerabilities that can be exploited therapeutically. The ...
    • Discordance between oncotype DX recurrence score and RSPC for predicting residual risk of recurrence in ER-positive breast cancer. 

      Dodson, A; Okonji, D; Assersohn, L; Rigg, A; Sheri, A; Turner, N; Smith, I; Parton, M; Dowsett, M (2018-02)
      PURPOSE:Oncotype DX, a gene expression assay widely employed to aid decision making on adjuvant chemotherapy use in patients with primary oestrogen receptor-positive (ER+) breast cancer, produces a recurrence score (RS) ...
    • Discovery of naturally occurring ESR1 mutations in breast cancer cell lines modelling endocrine resistance. 

      Martin, L-A; Ribas, R; Simigdala, N; Schuster, E; Pancholi, S; Tenev, T; Gellert, P; Buluwela, L; Harrod, A; Thornhill, A; Nikitorowicz-Buniak, J; Bhamra, A; Turgeon, M-O; Poulogiannis, G; Gao, Q; Martins, V; Hills, M; Garcia-Murillas, I; Fribbens, C; Patani, N; Li, Z; Sikora, MJ; Turner, N; Zwart, W; Oesterreich, S; Carroll, J; Ali, S; Dowsett, M (2017-11-30)
      Resistance to endocrine therapy remains a major clinical problem in breast cancer. Genetic studies highlight the potential role of estrogen receptor-α (ESR1) mutations, which show increased prevalence in the metastatic, ...
    • Discovery of Selective Estrogen Receptor Covalent Antagonists for the Treatment of ERαWT and ERαMUT Breast Cancer. 

      Puyang, X; Furman, C; Zheng, GZ; Wu, ZJ; Banka, D; Aithal, K; Agoulnik, S; Bolduc, DM; Buonamici, S; Caleb, B; Das, S; Eckley, S; Fekkes, P; Hao, M-H; Hart, A; Houtman, R; Irwin, S; Joshi, JJ; Karr, C; Kim, A; Kumar, N; Kumar, P; Kuznetsov, G; Lai, WG; Larsen, N; Mackenzie, C; Martin, L-A; Melchers, D; Moriarty, A; Nguyen, T-V; Norris, J; O'Shea, M; Pancholi, S; Prajapati, S; Rajagopalan, S; Reynolds, DJ; Rimkunas, V; Rioux, N; Ribas, R; Siu, A; Sivakumar, S; Subramanian, V; Thomas, M; Vaillancourt, FH; Wang, J; Wardell, S; Wick, MJ; Yao, S; Yu, L; Warmuth, M; Smith, PG; Zhu, P; Korpal, M (2018-09)
      Mutations in estrogen receptor alpha (ERα) that confer resistance to existing classes of endocrine therapies are detected in up to 30% of patients who have relapsed during endocrine treatments. Because a significant ...
    • Disruption of the Interaction of RAS with PI 3-Kinase Induces Regression of EGFR-Mutant-Driven Lung Cancer. 

      Murillo, MM; Rana, S; Spencer-Dene, B; Nye, E; Stamp, G; Downward, J (2018-12)
      RAS family GTPases contribute directly to the regulation of type I phosphoinositide 3-kinases (PI3Ks) via RAS-binding domains in the PI3K catalytic p110 subunits. Disruption of this domain of p110α impairs RAS-mutant-onc ...